Edgewise Therapeutics Plunges 18.58% Despite Positive Clinical Data

Edgewise Therapeutics' stock price dropped 18.58% in pre-market trading on April 2, 2025, marking a significant decline for the biopharmaceutical company.

JPMorgan recently increased its price target for Edgewise Therapeutics from $44.00 to $45.00, maintaining an Overweight rating. This move reflects the firm's optimism about the company's ongoing developments and potential for growth.

Edgewise Therapeutics announced positive top-line data from the EDG-7500 clinical trial, which focuses on muscle disease treatments. This news has been well-received by investors, contributing to the company's overall positive performance in recent months.

Edgewise Therapeutics ended the year with a 175% increase in stock value, driven by positive clinical trial results in genetic heart disease and neuromuscular disorders. The company's Phase 3 trial for Amolyt has also shown promising results, further bolstering investor confidence.